U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts

Alnylam Pharmaceuticals

Market Cap: US$30.6b

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Insmed

Market Cap: US$28.1b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Praxis Precision Medicines

Market Cap: US$10.3b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Summit Therapeutics

Market Cap: US$10.2b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Vaxcyte

Market Cap: US$8.9b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

ImmunityBio

Market Cap: US$8.2b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

Cogent Biosciences

Market Cap: US$6.5b

A clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.

CRISPR Therapeutics

Market Cap: US$5.2b

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

Celcuity

Market Cap: US$4.6b

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

Tango Therapeutics

Market Cap: US$4.3b

A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.

Legend Biotech

Market Cap: US$4.2b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Viking Therapeutics

Market Cap: US$3.9b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Structure Therapeutics

Market Cap: US$3.8b

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

NewAmsterdam Pharma

Market Cap: US$3.3b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

Alumis

Market Cap: US$3.2b

A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

Beam Therapeutics

Market Cap: US$2.7b

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

SELLAS Life Sciences Group

Market Cap: US$2.6b

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

Kodiak Sciences

Market Cap: US$2.6b

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Nektar Therapeutics

Market Cap: US$2.5b

A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

Ultragenyx Pharmaceutical

Market Cap: US$2.5b

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

BioCryst Pharmaceuticals

Market Cap: US$2.5b

A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

Nuvation Bio

Market Cap: US$2.4b

A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.

Precigen

Market Cap: US$2.4b

A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Mineralys Therapeutics

Market Cap: US$2.4b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

Ocular Therapeutix

Market Cap: US$2.3b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Kailera Therapeutics

Market Cap: US$2.3b

Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

Vera Therapeutics

Market Cap: US$2.3b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

Palvella Therapeutics

Market Cap: US$2.2b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

ADMA Biologics

Market Cap: US$2.1b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Zenas BioPharma

Market Cap: US$2.1b

A clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.

Generate Biomedicines

Market Cap: US$2.1b

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.

Biohaven

Market Cap: US$2.0b

A biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

Taysha Gene Therapies

Market Cap: US$2.0b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

Kardigan

Market Cap: US$2.0b

Operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.

COMPASS Pathways

Market Cap: US$1.9b

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

Trulieve Cannabis

Market Cap: US$1.9b

Operates as a cannabis retailer in the United States.